Last reviewed · How we verify
ADM
ADM (doxorubicin) is an anthracycline chemotherapy agent that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death.
ADM (doxorubicin) is an anthracycline chemotherapy agent that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death. Used for Soft tissue sarcoma (as part of combination chemotherapy), Various solid tumors and hematologic malignancies.
At a glance
| Generic name | ADM |
|---|---|
| Also known as | Adriamycin |
| Sponsor | Italian Sarcoma Group |
| Drug class | Anthracycline chemotherapy agent |
| Target | Topoisomerase II; DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Doxorubicin works by inserting itself between DNA base pairs (intercalation) and blocking the enzyme topoisomerase II, which normally allows DNA strands to separate during replication and transcription. This dual mechanism prevents DNA synthesis and repair, triggering apoptosis in rapidly dividing cancer cells. It is particularly effective against a broad range of malignancies including sarcomas, lymphomas, and solid tumors.
Approved indications
- Soft tissue sarcoma
- Bone sarcoma
- Various solid tumors and hematologic malignancies
Common side effects
- Cardiotoxicity / cardiomyopathy
- Myelosuppression (neutropenia, anemia, thrombocytopenia)
- Nausea and vomiting
- Alopecia
- Mucositis
- Extravasation injury
Key clinical trials
- "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" (NA)
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Project Tendura: The Impact of Blood Flow Restriction Resistance Training (BFR-RT) in Patients With Achilles Tendon Rupture (ATR) Repair (NA)
- Effect of Scalp Block on Intraoperative Hemodynamics and Postoperative Pain in Craniotomy Patients" (NA)
- The EDICT Trial - Therapy for Inflammatory Bowel Disease Flares (NA)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |